Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.

SG&A Expenses: A Decade of Growth and Strategy

__timestampIntra-Cellular Therapies, Inc.Johnson & Johnson
Wednesday, January 1, 20141033767921954000000
Thursday, January 1, 20151818728621203000000
Friday, January 1, 20162475806319945000000
Sunday, January 1, 20172366695721420000000
Monday, January 1, 20183009985522540000000
Tuesday, January 1, 20196494762522178000000
Wednesday, January 1, 202018636344422084000000
Friday, January 1, 202127261104020118000000
Saturday, January 1, 202235878200019046000000
Sunday, January 1, 202340986400020112000000
Monday, January 1, 202421969000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, understanding the financial dynamics of companies is crucial. Johnson & Johnson, a titan in the industry, has consistently maintained high Selling, General, and Administrative (SG&A) expenses, averaging around $21 billion annually from 2014 to 2023. This reflects their expansive global operations and robust marketing strategies. In contrast, Intra-Cellular Therapies, Inc., a smaller player, has seen its SG&A expenses grow significantly, from approximately $10 million in 2014 to over $400 million in 2023, marking a staggering 3,900% increase. This growth underscores their aggressive expansion and investment in market penetration. The data highlights the contrasting scales and strategies of these companies, offering insights into their operational priorities and market positioning. As the pharmaceutical landscape evolves, these financial trends provide a window into the strategic decisions shaping the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025